PRNewswire (Thu, 28-Mar 7:00 AM ET)
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Globe Newswire (Thu, 28-Mar 6:00 AM ET)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)
TipRanks (Wed, 27-Mar 7:00 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 27-Mar 6:20 AM ET)
FDA grants priority review for Syndax leukemia drug, sets action date
Seeking Alpha News (Tue, 26-Mar 5:11 PM ET)
PRNewswire (Tue, 26-Mar 4:05 PM ET)
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
PRNewswire (Mon, 18-Mar 7:00 AM ET)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Fri, 1-Mar 4:05 PM ET)
Business Wire (Tue, 27-Feb 4:08 PM ET)
Syndax Announces Participation at Two Upcoming Investor Conferences
PRNewswire (Mon, 26-Feb 7:00 AM ET)
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Syndax Pharmaceuticals trades on the NASDAQ stock market under the symbol SNDX.
As of March 28, 2024, SNDX stock price climbed to $24.12 with 327,280 million shares trading.
SNDX has a beta of 1.92, meaning it tends to be more sensitive to market movements. SNDX has a correlation of 0.22 to the broad based SPY ETF.
SNDX has a market cap of $2.05 billion. This is considered a Mid Cap stock.
In the last 3 years, SNDX stock traded as high as $29.86 and as low as $11.22.
The top ETF exchange traded funds that SNDX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
SNDX has underperformed the market in the last year with a price return of +9.9% while the SPY ETF gained +33.7%. However, in the short term, SNDX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.3% vs +10.2% return in SPY. But in the last 2 weeks, SNDX shares have been beat by the market, returning +1.5% compared to an SPY return of +1.7%.
SNDX support price is $22.22 and resistance is $23.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNDX stock will trade within this expected range on the day.